

Special Issue

Cancer Biomarkers—Detection and Evaluation of Response to Therapy

Message from the Guest Editors

Cancer biomarkers are increasingly important in the detection of earlier stages of disease; they are essential, and still in need of discovery, in the optimal dosing of anti-cancer drugs, predicting treatment-related toxicity, and selecting therapies that can most benefit either individual patients or subgroups with a particular cancer. This Special issue will explore past and present biomarkers, novel biomarkers, and the use of biomarkers with different diagnostic and treatment options to improve the detection and management of cancer.

Guest Editors

Dr. Giulio Francia

Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX, USA

Dr. Jianying Zhang

Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX, USA

Deadline for manuscript submissions

30 June 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/199610

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)